Frank Bartel

Medicine · Health Sciences

35h-index4.5kcitations103works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(34), RNA modifications and cancer(27), Sarcoma Diagnosis and Treatment(20), Cancer Genomics and Diagnostics(12), Epigenetics and DNA Methylation(10)

Publications103 total

Supplementary Table 2 from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
Supplementary Table 1 from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
Supplementary Tables 1-6 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Supplementary Figure 3 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Supplementary Table 1 from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
Supplementary Figure 3 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Data from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
Supplementary Figure 2 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Supplementary Methods, Figure Legends 1-3, Table Legends 1-6 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Supplementary Tables 1-6 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Data from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Supplementary Figure 1 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Supplementary Table 3 from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
Supplementary Table 2 from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
Supplementary Table 3 from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
Supplementary Methods, Figure Legends 1-3, Table Legends 1-6 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Data from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Supplementary Figure 2 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Supplementary Figure 1 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
2023Open Access
Data from An Illegitimate microRNA Target Site within the 3′ UTR of <i>MDM4</i> Affects Ovarian Cancer Progression and Chemosensitivity
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Helge Täubert(34), Matthias Bache(23), Peter Würl(22), Axel Meye(18), Matthias Kappler(17), Hannelore Schmidt(16), Anja Böhnke(6), Karen Blümke(6), Linda C. Harris(5), Steffen Hauptmann(5), H Schmidt(5), Christine Lautenschläger(5), Gareth L. Bond(4), Charles E. Schwartz(4), Barbara R. DuPont(4), S. Füssel(4), Hans-Jürgen Holzhausen(4), Elisabeth E. Bond(3), Peter Wuerl(3), Arnold J. Levine(3)